Craig Coleman
Professor/Pharmacy Practice

Are you Craig Coleman?

How to update your information.
Scholarly Contributions

620 Scholarly Contributions

419
Journal Articles
137
Poster/Presentations
41
Other Scholarly Works
12
Digital and Electronic Media, Social Media, Blog, Podcast, Magazine/Trade Publications
6
Conference Proceedings
5
Book Chapters
Rivaroxaban Versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients
2020
Craig Coleman
Research Type: Poster/Presentation

Do Difference in Baseline Clinical Severity of Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage Predict Andexanet Versus Four-Factor Prothrombin Complex Concentrate Administration?
2020
William L Baker Jr., Olivia S Costa, Craig Coleman
Research Type: Poster/Presentation

“RIVAROXABAN VERSUS WARFARIN IN AFRICAN AMERICAN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION”. Event: ACC 2020, Chicago.
2020
Craig Coleman
Research Type: Poster/Presentation

“REAL-WORLD MANAGEMENT OF ORAL FACTOR XA INHIBITOR BLEEDING-RELATED HOSPITALIZATIONS WITH ANDEXANET ALFA OR 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE”. Event: ACC 2020, Chicago.
2020
Craig Coleman
Research Type: Poster/Presentation

Effectiveness and Safety of Rivaroxaban Compared to Low Molecular-Weight Heparin in Patients with Cancer-Associated Venous Thromboembolism: A Real-World Analysis.
2020
Craig Coleman
Research Type: Poster/Presentation

Do Differences in Baseline Clinical Severity of Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage Predict Andexanet Alfa Versus Four-Factor Prothrombin Complex Concentrate Administration?
2020
Craig Coleman
Research Type: Poster/Presentation

“FOUR-YEAR INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ATRIAL FIBRILLATION PATIENTS WITH OR AT HIGH RISK FOR ATHEROSCLEROSIS”. Event: ACC 2020, Chicago.
2020
Craig Coleman
Research Type: Poster/Presentation

Evidence Summary
2019
Adrian V Hernandez Diaz, Craig Coleman, Brandon K Martinez, Mark X Cicero, Richard A Kamin, Diana Sobieraj, Benjamin Miao, William L Baker Jr.
Research Type: Book Chapter

Treatment patterns, glycemic control & bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients.
2019
O Baser, Craig Coleman, L Wang, J Cai, M Ingham, S Pandya, B Bookhart
Research Type: Journal Article

The impact of non-medical switching among ambulatory patients: an updated systematic literature review.
2019
M Ingham, S Martin, E Nguyen, E R Weeda, B K Bookhart, Craig Coleman, Diana Sobieraj
Research Type: Journal Article

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.
2019
C Crivera, J Schein, W F Peacock, G J Fermann, O Baser, P Wells, L Wang, Craig Coleman
Research Type: Journal Article

Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
2019
D Eriksson, B K Martinez, Craig Coleman, N A Sood, William L Baker Jr., A K Meinecke, Thomas Bunz
Research Type: Journal Article

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.
2019
D C Steffens, Craig Coleman, K M Berg, A V Hernandez, Diana Sobieraj, William L Baker Jr., B K Martinez, J S Ross
Research Type: Journal Article

The value of sPESI for risk stratification in patients with pulmonary embolism.
2019
O Baser, J Schein, Craig Coleman, P Wells, C Crivera, W F Peacock, L Wang, G J Fermann
Research Type: Journal Article

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
2019
J B Briere, L Fauchier, P Levy, O Wu, A Millier, K Bowrin, M Toumi, V Taieb, Craig Coleman
Research Type: Journal Article

Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
2019
Thomas Bunz, Candice Kohn, J Beyer-Westendorf, Craig Coleman
Research Type: Journal Article

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
2019
P Lefebvre, E D Peterson, V Ashton, P Oyefesobi, H M Rozjabek, D Lejeune, Craig Coleman, Z Yuan, J R Schein, G Germain, F Laliberté
Research Type: Journal Article

Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes.
2019
N A Sood, Craig Coleman, Thomas Bunz, William L Baker Jr., A K Meinecke, D Eriksson, J Beyer-Westendorf
Research Type: Journal Article

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE.
2019
Thomas Bunz, J Beyer-Westendorf, William L Baker Jr., Craig Coleman
Research Type: Journal Article

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
2019
D Eriksson, Craig Coleman, William L Baker Jr., B K Martinez, A K Meinecke, M J Alberts, Thomas Bunz
Research Type: Journal Article